News:  Plus Therapeutics Announces Plans for Treating Pediatric Brain Cancer

Pediatric Brain Cancer:
U.S. Phase 1 Clinical Trial

 

Not Yet Recruiting

Pediatric Brain
Cancer:  U.S. Phase
1 Clinical Trial

 

Not Yet Recruiting

Pediatric
Brain
Cancer:
U.S. Phase
1 Clinical
Trial

 

Not Yet Recruiting

Trial Information

Pediatric brain cancer is relatively rare. However, cancer is the leading cause of death by disease among children in the U.S.  Brain and spinal cord tumors are the 2nd most common cancers in children, accounting for ~26% of childhood cancers.

Plus Therapeutics is developing the Rhenium (186Re) Obisbemeda radiotherapeutic for the treatment of rare, frequently fast-growing pediatric brain and spinal cord tumors with a poor prognosis – ependymoma and high-grade glioma (HGG).  The ReSPECT-PBC (Pediatric Brain Cancer) U.S. Phase 1 Clinical Trial is planned to start in 2024.

“Children with brain tumors have limited options & 186RNL delivered with a minimally invasive procedure could be an important new potential option for these patients.”

Michael G. DeCuypere, MD, PhD, FAANS

Northwestern University Feinberg School of Medicine

Principal Investigators

There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.

Ashley S. Plant, M.D.

Lurie Children’s Hospital of Chicago

SPECIALTIES:  CANCER & BLOOD DISORDERS

Ashley S. Plant, M.D. is an attending physician in neuro-oncology at Ann and Robert H. Lurie Children’s Hospital of Chicago and is an Assistant Professor of Pediatrics at Northwestern University. Dr. Plant received her medical degree from Stanford University School of Medicine. She completed her pediatrics residency at University of California, Los Angeles and her pediatric hematology/oncology fellowship at Dana Farber Cancer Institute/Boston Children’s Hospital. She completed additional training in neuro-oncology at Dana Farber Cancer Institute. Her research focus includes immunotherapy and the immune microenvironment as well as early phase clinical trial design for pediatric brain tumors.

Trial Locations

Please visit this website regularly for updates as new locations are added.

Lurie Children’s Hospital

Chicago, Illinois

What Can You Do Next?

Participating in a clinical trial is an important decision.  If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Request Information

3 + 14 =

News

 

December 12, 2023

Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses

November 29, 2023

Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe

  • Presentation titled “Re-186 Radiolabelled NanoLiposomes for Rare Brain and Spinal Cord Tumors”

October 25, 2023

Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

September 8, 2023

Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay

August 8, 2023

Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference

July 27, 2023

Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference

  • Presentations titled: [LMAP-21] Preliminary Clinical Data in the Phase 1/2a Dose Escalation Trial of Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM): The ReSPECT-LM Trial; [TIPS-23] Safety and Feasibility Results from a Phase 1/2 Clinical Trial of Rhenium (186Re) Obisbemeda (186RNL) in Recurrent Glioma: The ReSPECT-GBM Trial; [TIPS-22] A two-part, Phase 1 study of Rhenium (186Re) Obisbemeda (186RNL) delivered by convection enhanced delivery (CED) for recurrent, refractory, or progressive childhood ependymoma and high-grade glioma (HGG)

June 8, 2023

Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting

  • Plus Therapeutics announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois.

November 19, 2022

Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

  • In November 2022, Plus Therapeutics, in collaboration with Lurie Children’s Hospital investigators, anticipates filing an Investigational New Drug (IND) application for a first-in-child Phase 1/2a clinical trial to determine the maximum tolerated dose, safety, tolerability and early efficacy of rhenium (186Re) obisbemeda in supratentorial recurrent or progressive pediatric ependymoma and high-grade glioma (HGG) in up to 24 patients initially. These plans were presented in a poster titled, “A two-part, Phase 1 study of Rhenium-186 NanoLiposome (186RNL) delivered by convection enhanced delivery (CED) for recurrent or progressive childhood ependymoma and high-grade glioma (HGG) [CTNI-19]”.

August 21, 2021

Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer

June 10, 2021

Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference

Updates

SNMMI

Reminder to come by Plus Therapeutics at the SNMMI 2024 Annual Meeting in Toronto at Booth #1948 Learn about the latest ReSPECT-LM Clinical Trial data for Leptomeningeal Metastases and view our newest poster in the poster hall Two accepted abstracts titled: "Rhenium...

read more

Gliobalstoma AKA GBM Podcast

📣 NEW GLIOBLASTOMA PODCAST EPISODE! Link to listen: https://bit.ly/4dZjfUD Thank you to @glioblastomaakagbm by @glioblastomaresearchorg for hosting our very own Dr. Marc Hedrick, President and CEO of Plus Therapeutics in your latest episode. Dr. Hedrick brings his...

read more

Brain Tumor Resources

In honor of #BrainTumorAwarenessMonth, we would like to reshare some great educational, support and financial resources for patients and caregivers fighting a brain tumor diagnosis. More information can be found on our website at ReSPECT-Trials.com along with...

read more

Replay Patient Webinar

#ICYMI: Replay the #Glioblastoma Patient Webinar from last week, hosted by Dr. Al Musella. The presentation included information about the ReSPECT-GBM clinical trial's promising targeted radiotherapeutic working to treat Recurrent Glioblastoma and included a lively...

read more

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.